An adoptive immunotherapy using ex vivo-generated regulatory T cells may
be used for the suppression of undesireable immune response. T cells are
to be obtained from the patient's blood, and upon exposure to a set of
toxins from the pathogen A. actinomycetemcomitans, the population of
regulatory T cells will be enriched ex vivo and adoptively transferred
back to the patient. The novel aspect of the present invention is that it
generates large numbers of type 1 regulatory T cells, which secrete
Interleukin-10.